ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

Black History Month Conversation with The Cancer Letter

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

Nearly 30 years ago, while completing an assignment for his master’s degree in public health, Brian Rivers discovered he had a family history of prostate cancer.

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Clinical Roundup

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, may be key in helping the immune system fight tumors in ovarian cancer. The study, published in Science Advances, could improve treatment approaches for this type of cancer.

February 21, 2025

Vol.51 No.07

Drugs & Targets

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

FDA granted priority review to Boehringer Ingelheim’s new drug application for BI 1810631 (zongertinib) for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have HER2 mutations and who have received prior systemic therapy.

February 21, 2025

Vol.51 No.07

White House

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology

Earlier this week, Robert F. Kennedy Jr. was confirmed as secretary of Health and Human Services amid many resignations at federal health agencies and cancellations of NIH and NCAB meetings. All of this happened at a time when the Trump administration is reportedly preparing to fire thousands of HHS workers.

February 14, 2025

Vol.51 No.06

By Claire Marie Porter and Jacquelyn Cobb

Clinical Roundup

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

February 14, 2025

Vol.51 No.06

ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

YOU MAY BE INTERESTED IN

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Renew today!

Subscriber content

Never miss an issue!

Login

ODAC says prostate cancer patients who lack proven BRCA mutation shouldn’t get PARP inhibitor

YOU MAY BE INTERESTED IN

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America“It gives America, in part, its identity.”

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Mayo Clinic researchers identify new immunotherapy target for ovarian cancer

FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, genderOne month in: Trump’s impact on oncology

Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds

Never miss an issue!

Login

Brian Rivers: Celebrating Black history reinforces the dynamic culture of America
“It gives America, in part, its identity.”

RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, gender
One month in: Trump’s impact on oncology